Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Verastem ( (VSTM) ) has issued an update.
On November 4, 2025, Verastem Oncology reported its third-quarter financial results and business updates. The company achieved net product revenue of $11.2 million from the launch of AVMAPKI FAKZYNJA CO-PACK, indicating strong market adoption. Verastem is advancing its clinical pipeline, particularly the KRAS G12D inhibitor VS-7375, which showed promising preliminary safety and efficacy results. The company is also expanding its trials, including a combination study with cetuximab for advanced solid tumors, and anticipates several key data readouts in 2026.
The most recent analyst rating on (VSTM) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Verastem stock, see the VSTM Stock Forecast page.
Spark’s Take on VSTM Stock
According to Spark, TipRanks’ AI Analyst, VSTM is a Neutral.
Verastem’s overall stock score is primarily impacted by its weak financial performance, characterized by ongoing losses and negative equity. However, positive technical indicators and recent corporate events, such as the $75M private placement, provide some optimism for future growth. Valuation remains constrained by negative earnings, but strategic initiatives and product development efforts could drive improvements. The stock represents a speculative opportunity, with potential upside if financial health and operational efficiencies improve.
To see Spark’s full report on VSTM stock, click here.
More about Verastem
Verastem Oncology is a biopharmaceutical company focused on developing new medicines for patients with RAS/MAPK pathway-driven cancers.
Average Trading Volume: 2,463,625
Technical Sentiment Signal: Buy
Current Market Cap: $609.3M
Learn more about VSTM stock on TipRanks’ Stock Analysis page.